In patients with multivessel coronary artery disease and in vivo coronary 18F-fluoride activity, we found no evidence that intensification of antiplatelet therapy using ticagrelor 90 mg twice daily reduces plasma high-sensitivity cardiac troponin I concentration at 30 days or 1 year. The gene discussed is TNNI3; the disease is coronary artery disorder.